PubMed:23999440
Annnotations
sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| TextSentencer_T1 | 0-83 | Sentence | denotes | HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. |
| TextSentencer_T2 | 84-360 | Sentence | denotes | Hypoxia occurs frequently in human cancers and induces adaptive changes in cell metabolism that include a switch from oxidative phosphorylation to glycolysis, increased glycogen synthesis, and a switch from glucose to glutamine as the major substrate for fatty acid synthesis. |
| TextSentencer_T3 | 361-524 | Sentence | denotes | This broad metabolic reprogramming is coordinated at the transcriptional level by HIF-1, which functions as a master regulator to balance oxygen supply and demand. |
| TextSentencer_T4 | 525-771 | Sentence | denotes | HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy. |
| TextSentencer_T5 | 772-915 | Sentence | denotes | Inhibitors of HIF-1 or metabolic enzymes may impair the metabolic flexibility of cancer cells and make them more sensitive to anticancer drugs. |
| T1 | 0-83 | Sentence | denotes | HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. |
| T2 | 84-360 | Sentence | denotes | Hypoxia occurs frequently in human cancers and induces adaptive changes in cell metabolism that include a switch from oxidative phosphorylation to glycolysis, increased glycogen synthesis, and a switch from glucose to glutamine as the major substrate for fatty acid synthesis. |
| T3 | 361-524 | Sentence | denotes | This broad metabolic reprogramming is coordinated at the transcriptional level by HIF-1, which functions as a master regulator to balance oxygen supply and demand. |
| T4 | 525-771 | Sentence | denotes | HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy. |
| T5 | 772-915 | Sentence | denotes | Inhibitors of HIF-1 or metabolic enzymes may impair the metabolic flexibility of cancer cells and make them more sensitive to anticancer drugs. |
DisGeNET
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T0 | 661-664 | gene:207 | denotes | AKT |
| T1 | 726-744 | disease:C0178874 | denotes | cancer progression |
| T2 | 656-660 | gene:5291 | denotes | PI3K |
| T3 | 726-744 | disease:C0178874 | denotes | cancer progression |
| T4 | 656-660 | gene:5290 | denotes | PI3K |
| T5 | 726-744 | disease:C0178874 | denotes | cancer progression |
| T6 | 656-660 | gene:5293 | denotes | PI3K |
| T7 | 726-744 | disease:C0178874 | denotes | cancer progression |
| T8 | 525-530 | gene:3091 | denotes | HIF-1 |
| T9 | 552-558 | disease:C0006826 | denotes | cancer |
| T10 | 525-530 | gene:3091 | denotes | HIF-1 |
| T11 | 552-558 | disease:C1306459 | denotes | cancer |
| T12 | 525-530 | gene:29072 | denotes | HIF-1 |
| T13 | 552-558 | disease:C0006826 | denotes | cancer |
| T14 | 525-530 | gene:29072 | denotes | HIF-1 |
| T15 | 552-558 | disease:C1306459 | denotes | cancer |
| T16 | 656-660 | gene:5294 | denotes | PI3K |
| T17 | 726-744 | disease:C0178874 | denotes | cancer progression |
| T18 | 525-530 | gene:29072 | denotes | HIF-1 |
| T19 | 726-744 | disease:C0178874 | denotes | cancer progression |
| T20 | 592-595 | gene:7428 | denotes | VHL |
| T21 | 726-744 | disease:C0178874 | denotes | cancer progression |
| T22 | 525-530 | gene:3091 | denotes | HIF-1 |
| T23 | 726-744 | disease:C0178874 | denotes | cancer progression |
| T24 | 786-791 | gene:29072 | denotes | HIF-1 |
| T25 | 853-859 | disease:C1306459 | denotes | cancer |
| T26 | 786-791 | gene:29072 | denotes | HIF-1 |
| T27 | 853-859 | disease:C0006826 | denotes | cancer |
| T28 | 786-791 | gene:3091 | denotes | HIF-1 |
| T29 | 853-859 | disease:C1306459 | denotes | cancer |
| T30 | 786-791 | gene:3091 | denotes | HIF-1 |
| T31 | 853-859 | disease:C0006826 | denotes | cancer |
| R1 | T0 | T1 | associated_with | AKT,cancer progression |
| R2 | T2 | T3 | associated_with | PI3K,cancer progression |
| R3 | T4 | T5 | associated_with | PI3K,cancer progression |
| R4 | T6 | T7 | associated_with | PI3K,cancer progression |
| R5 | T8 | T9 | associated_with | HIF-1,cancer |
| R6 | T10 | T11 | associated_with | HIF-1,cancer |
| R7 | T12 | T13 | associated_with | HIF-1,cancer |
| R8 | T14 | T15 | associated_with | HIF-1,cancer |
| R9 | T16 | T17 | associated_with | PI3K,cancer progression |
| R10 | T18 | T19 | associated_with | HIF-1,cancer progression |
| R11 | T20 | T21 | associated_with | VHL,cancer progression |
| R12 | T22 | T23 | associated_with | HIF-1,cancer progression |
| R13 | T24 | T25 | associated_with | HIF-1,cancer |
| R14 | T26 | T27 | associated_with | HIF-1,cancer |
| R15 | T28 | T29 | associated_with | HIF-1,cancer |
| R16 | T30 | T31 | associated_with | HIF-1,cancer |
PubmedHPO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 119-126 | HP_0002664 | denotes | cancers |
| T2 | 552-558 | HP_0002664 | denotes | cancer |
| T3 | 568-573 | HP_0002664 | denotes | tumor |
| T4 | 726-732 | HP_0002664 | denotes | cancer |
| T5 | 853-859 | HP_0002664 | denotes | cancer |
DisGeNET5_gene_disease
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 23999440-3#0#5#gene3091 | 525-530 | gene3091 | denotes | HIF-1 |
| 23999440-3#0#5#gene29072 | 525-530 | gene29072 | denotes | HIF-1 |
| 23999440-3#131#135#gene5290 | 656-660 | gene5290 | denotes | PI3K |
| 23999440-3#131#135#gene5291 | 656-660 | gene5291 | denotes | PI3K |
| 23999440-3#131#135#gene5293 | 656-660 | gene5293 | denotes | PI3K |
| 23999440-3#131#135#gene5294 | 656-660 | gene5294 | denotes | PI3K |
| 23999440-3#67#70#gene7428 | 592-595 | gene7428 | denotes | VHL |
| 23999440-3#136#139#gene207 | 661-664 | gene207 | denotes | AKT |
| 23999440-3#201#219#diseaseC0178874 | 726-744 | diseaseC0178874 | denotes | cancer progression |
| 0#5#gene3091201#219#diseaseC0178874 | 23999440-3#0#5#gene3091 | 23999440-3#201#219#diseaseC0178874 | associated_with | HIF-1,cancer progression |
| 0#5#gene29072201#219#diseaseC0178874 | 23999440-3#0#5#gene29072 | 23999440-3#201#219#diseaseC0178874 | associated_with | HIF-1,cancer progression |
| 131#135#gene5290201#219#diseaseC0178874 | 23999440-3#131#135#gene5290 | 23999440-3#201#219#diseaseC0178874 | associated_with | PI3K,cancer progression |
| 131#135#gene5291201#219#diseaseC0178874 | 23999440-3#131#135#gene5291 | 23999440-3#201#219#diseaseC0178874 | associated_with | PI3K,cancer progression |
| 131#135#gene5293201#219#diseaseC0178874 | 23999440-3#131#135#gene5293 | 23999440-3#201#219#diseaseC0178874 | associated_with | PI3K,cancer progression |
| 131#135#gene5294201#219#diseaseC0178874 | 23999440-3#131#135#gene5294 | 23999440-3#201#219#diseaseC0178874 | associated_with | PI3K,cancer progression |
| 67#70#gene7428201#219#diseaseC0178874 | 23999440-3#67#70#gene7428 | 23999440-3#201#219#diseaseC0178874 | associated_with | VHL,cancer progression |
| 136#139#gene207201#219#diseaseC0178874 | 23999440-3#136#139#gene207 | 23999440-3#201#219#diseaseC0178874 | associated_with | AKT,cancer progression |
DisGeNet-2017-sample
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T2921 | 525-530 | gene:3091 | denotes | HIF-1 |
| T2922 | 726-744 | disease:C0178874 | denotes | cancer progression |
| T2923 | 656-660 | gene:5290 | denotes | PI3K |
| R1 | T2921 | T2922 | associated_with | HIF-1,cancer progression |
| R2 | T2921 | T2922 | associated_with | HIF-1,cancer progression |
| R3 | T2923 | T2922 | associated_with | PI3K,cancer progression |
| R4 | T2923 | T2922 | associated_with | PI3K,cancer progression |
| R5 | T2923 | T2922 | associated_with | PI3K,cancer progression |
| R6 | T2923 | T2922 | associated_with | PI3K,cancer progression |